PTC Therapeutics Inc
NASDAQ:PTCT
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
21.48
44.87
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
PTC Therapeutics Inc
Wall Street
Price Targets
PTCT Price Targets Summary
PTC Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
PTCT
is 45.9 USD
with a low forecast of 26.26 USD and a high forecast of 69.3 USD.
PTCT Last Price Targets
PTC Therapeutics Inc
The latest public price target was made on Oct 11, 2024 by
Jeffrey Hung
from
Morgan Stanley
,
who expects
PTCT
stock to
rise by 4%
over the next 12 months.
You can read more about this price target by viewing
the article on TheFly.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Jeffrey Hung
Morgan Stanley
|
45
USD
Upside 4% |
1 month ago
Oct 11, 2024
|
PTC Therapeutics price target raised to $45 from $32 at Morgan Stanley
TheFly
|
Colin Bristow
UBS
|
47
USD
Upside 8% |
2 months ago
Aug 26, 2024
|
UBS Upgrades PTC Therapeutics (PTCT) to Buy
StreetInsider
|
|
Jeffrey Hung
Morgan Stanley
|
32
USD
Downside 26% |
4 months ago
Jul 12, 2024
|
PTC Therapeutics price target raised to $32 from $30 at Morgan Stanley
TheFly
|
Paul Choi
Goldman Sachs
|
32
USD
Downside 26% |
6 months ago
May 20, 2024
|
PTC Therapeutics (PTCT) PT Raised to $32 at Goldman Sachs, Reiterates Sell
StreetInsider
|
Kelly Shi
Jefferies
|
46
USD
Upside 6% |
6 months ago
May 20, 2024
|
PTC Therapeutics (PTCT) PT Raised to $46 at Jefferies
StreetInsider
|
|
Jeffrey Hung
Morgan Stanley
|
30
USD
Downside 31% |
6 months ago
Apr 26, 2024
|
Morgan Stanley Upgrades PTC Therapeutics (PTCT) to Equalweight
StreetInsider
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is PTCT's stock price target?
Price Target
45.9
USD
According to Wall Street analysts, the average 1-year price target for
PTCT
is 45.9 USD
with a low forecast of 26.26 USD and a high forecast of 69.3 USD.
What is PTC Therapeutics Inc's Revenue forecast?
Projected CAGR
-3%
For the last 8 years the
compound annual growth rate for
PTC Therapeutics Inc's revenue is
50%.
The projected
CAGR
for the next 3 years is
-3%.
You don't have any saved screeners yet
